Patents by Inventor Tatsuki Kashiwagi

Tatsuki Kashiwagi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050244939
    Abstract: The present invention relates to variant aldolase enzymes that are modified so as to produce IHOG, a process for producing an optically active IHOG using the same, and a process for producing an optically active monatin.
    Type: Application
    Filed: March 16, 2005
    Publication date: November 3, 2005
    Applicant: Ajinomoto Co., Inc.
    Inventors: Masakazu Sugiyama, Tatsuki Kashiwagi, Kenichi Mori, Eiichiro Suzuki
  • Publication number: 20050112731
    Abstract: O-acetylserine, L-cysteine and sulphurous compounds derived therefrom may be produced using a bacterium belonging to the genus Escherichia which harbors a mutant feedback-resistant serine acetyltransferases in which the amino acid sequence corresponding to positions from 89 to 96 in a wild-type serine acetyltransferase is replaced with any one of the amino acid sequences shown in SEQ ID NOS: 4 to 9, and feedback inhibition by L-cysteine in the bacterium is desensitized.
    Type: Application
    Filed: July 16, 2004
    Publication date: May 26, 2005
    Inventors: Tatsuki Kashiwagi, Yuko Kai, Kohki Ishikawa, Ei-ichiro Suzuki, Hiroshi Takagi, Mikhail Ziyatdinov, Ekaterina Redkina, Mikhail Gusyatiner
  • Publication number: 20040002144
    Abstract: The present invention relates to a method for designing and preparing mutant transglutaminases on the basis of the three-dimensional structure of MTG derived from Streptoverticillium mobaraense (MTG), and the mutant MTG thus prepared. The present invention provides a method for modifying MTG on the basis of the three-dimensional structure, and transglutaminase having reactivity on the substrate improved by the method. In the present invention, the binding site of MTG for the substrate is extrapolated based on the three-dimensional structure obtained by X-ray crystal structure analysis of MTG crystals, and the mutant transglutaminases are designed and produced by replacing, inserting or deleting amino acid residues positioned at the substrate-binding site of the transglutaminase.
    Type: Application
    Filed: February 13, 2003
    Publication date: January 1, 2004
    Applicant: AJINOMOTO CO. INC
    Inventors: Tatsuki Kashiwagi, Nobuhisa Shimba, Kohki Ishikawa, Ei-Ichiro Suzuki, Keiichi Yokoyama, Kazuo Hirayama